Medical - Devices
Compare Stocks
5 / 10Stock Comparison
AHCO vs EHAB vs OPCH vs UNH vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Healthcare Plans
Medical - Healthcare Plans
AHCO vs EHAB vs OPCH vs UNH vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Care Facilities | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $1.54B | $706M | $3.21B | $344.90B | $115.54B |
| Revenue (TTM) | $2.86B | $1.06B | $5.67B | $449.71B | $407.90B |
| Net Income (TTM) | $-80M | $-3M | $206M | $12.04B | $2.93B |
| Gross Margin | 1.8% | 36.1% | 18.0% | 18.8% | 13.9% |
| Operating Margin | 7.2% | 7.2% | 5.9% | 4.2% | 1.5% |
| Forward P/E | 12.6x | 22.9x | 11.2x | 20.7x | 12.4x |
| Total Debt | $1.90B | $500M | $0.00 | $78.39B | $93.59B |
| Cash & Equiv. | $106M | $44M | $233M | $24.36B | $8.51B |
AHCO vs EHAB vs OPCH vs UNH vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 22 | May 26 | Return |
|---|---|---|---|
| AdaptHealth Corp. (AHCO) | 100 | 62.6 | -37.4% |
| Enhabit, Inc. (EHAB) | 100 | 60.0 | -40.0% |
| Option Care Health,… (OPCH) | 100 | 73.8 | -26.2% |
| UnitedHealth Group … (UNH) | 100 | 74.0 | -26.0% |
| CVS Health Corporat… (CVS) | 100 | 97.7 | -2.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AHCO vs EHAB vs OPCH vs UNH vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, AHCO doesn't own a clear edge in any measured category.
EHAB is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 0.35, Low D/E 88.6%, current ratio 1.63x
- +42.3% vs OPCH's -35.3%
OPCH carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 13.0%, EPS growth 3.3%, 3Y rev CAGR 12.7%
- 95.0% 10Y total return vs UNH's 228.3%
- 13.0% revenue growth vs AHCO's -0.5%
- Lower P/E (11.2x vs 20.7x)
UNH ranks third and is worth considering specifically for dividends.
- 2.3% yield, 25-year raise streak, vs CVS's 3.0%, (3 stocks pay no dividend)
CVS is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 0.13, yield 3.0%
- Beta 0.13, yield 3.0%, current ratio 0.84x
- Beta 0.13 vs AHCO's 0.72, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.0% revenue growth vs AHCO's -0.5% | |
| Value | Lower P/E (11.2x vs 20.7x) | |
| Quality / Margins | 3.6% margin vs AHCO's -2.8% | |
| Stability / Safety | Beta 0.13 vs AHCO's 0.72, lower leverage | |
| Dividends | 2.3% yield, 25-year raise streak, vs CVS's 3.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +42.3% vs OPCH's -35.3% | |
| Efficiency (ROA) | 6.0% ROA vs AHCO's -1.8%, ROIC 15.3% vs 4.0% |
AHCO vs EHAB vs OPCH vs UNH vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AHCO vs EHAB vs OPCH vs UNH vs CVS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AHCO leads in 1 of 6 categories
OPCH leads 1 • CVS leads 1 • EHAB leads 0 • UNH leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — AHCO and EHAB each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 422.3x EHAB's $1.1B. OPCH is the more profitable business, keeping 3.6% of every revenue dollar as net income compared to AHCO's -2.8%. On growth, AHCO holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.9B | $1.1B | $5.7B | $449.7B | $407.9B |
| EBITDAEarnings before interest/tax | $504M | $98M | $406M | $23.2B | $10.5B |
| Net IncomeAfter-tax profit | -$80M | -$3M | $206M | $12.0B | $2.9B |
| Free Cash FlowCash after capex | $219M | $81M | $244M | $19.7B | $7.4B |
| Gross MarginGross profit ÷ Revenue | +1.8% | +36.1% | +18.0% | +18.8% | +13.9% |
| Operating MarginEBIT ÷ Revenue | +7.2% | +7.2% | +5.9% | +4.2% | +1.5% |
| Net MarginNet income ÷ Revenue | -2.8% | -0.3% | +3.6% | +2.7% | +0.7% |
| FCF MarginFCF ÷ Revenue | +7.7% | +7.6% | +4.3% | +4.4% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +41.2% | +1.9% | +1.3% | +2.0% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -140.0% | +2.9% | +3.6% | +0.7% | +63.1% |
Valuation Metrics
AHCO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 16.1x trailing earnings, OPCH trades at a 75% valuation discount to CVS's 65.1x P/E. On an enterprise value basis, AHCO's 5.6x EV/EBITDA is more attractive than UNH's 17.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.5B | $706M | $3.2B | $344.9B | $115.5B |
| Enterprise ValueMkt cap + debt − cash | $3.3B | $1.2B | $3.0B | $398.9B | $200.6B |
| Trailing P/EPrice ÷ TTM EPS | -21.73x | -152.21x | 16.15x | 28.72x | 65.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.61x | 22.86x | 11.18x | 20.71x | 12.39x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 5.56x | 13.47x | 7.28x | 17.10x | 13.38x |
| Price / SalesMarket cap ÷ Revenue | 0.47x | 0.67x | 0.57x | 0.77x | 0.29x |
| Price / BookPrice ÷ Book value/share | 1.00x | 1.24x | 2.53x | 3.40x | 1.53x |
| Price / FCFMarket cap ÷ FCF | 7.00x | 10.74x | 12.42x | 21.46x | 14.80x |
Profitability & Efficiency
OPCH leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
OPCH delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-5 for AHCO. UNH carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to AHCO's 1.25x. On the Piotroski fundamental quality scale (0–9), EHAB scores 6/9 vs CVS's 5/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.1% | -0.6% | +15.3% | +11.5% | +3.9% |
| ROA (TTM)Return on assets | -1.8% | -0.3% | +6.0% | +3.9% | +1.1% |
| ROICReturn on invested capital | +4.0% | +4.5% | +15.3% | +9.2% | +5.0% |
| ROCEReturn on capital employed | +5.0% | +6.0% | +12.8% | +9.7% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 6 | 5 |
| Debt / EquityFinancial leverage | 1.25x | 0.89x | — | 0.77x | 1.24x |
| Net DebtTotal debt minus cash | $1.8B | $456M | -$233M | $54.0B | $85.1B |
| Cash & Equiv.Liquid assets | $106M | $44M | $233M | $24.4B | $8.5B |
| Total DebtShort + long-term debt | $1.9B | $500M | $0 | $78.4B | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | 0.65x | 0.19x | 5.50x | 4.71x | 2.11x |
Total Returns (Dividends Reinvested)
Evenly matched — EHAB and CVS each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OPCH five years ago would be worth $12,311 today (with dividends reinvested), compared to $4,533 for AHCO. Over the past 12 months, EHAB leads with a +42.3% total return vs OPCH's -35.3%. The 3-year compound annual growth rate (CAGR) favors CVS at 12.2% vs OPCH's -10.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +16.9% | +51.7% | -36.4% | +13.6% | +14.7% |
| 1-Year ReturnPast 12 months | +34.8% | +42.3% | -35.3% | +0.8% | +37.4% |
| 3-Year ReturnCumulative with dividends | -6.4% | +2.2% | -27.2% | -17.8% | +41.2% |
| 5-Year ReturnCumulative with dividends | -54.7% | -44.8% | +23.1% | -0.9% | +19.8% |
| 10-Year ReturnCumulative with dividends | +16.5% | -44.8% | +95.0% | +228.3% | +6.6% |
| CAGR (3Y)Annualised 3-year return | -2.2% | +0.7% | -10.0% | -6.3% | +12.2% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than AHCO's 0.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.6% from its 52-week high vs OPCH's 55.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.72x | 0.35x | 0.41x | 0.60x | 0.13x |
| 52-Week HighHighest price in past year | $13.43 | $14.22 | $36.80 | $390.92 | $90.88 |
| 52-Week LowLowest price in past year | $8.06 | $6.47 | $18.01 | $234.60 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +84.1% | +97.0% | +55.7% | +97.2% | +99.6% |
| RSI (14)Momentum oscillator 0–100 | 43.4 | 59.7 | 24.7 | 76.9 | 70.0 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 1.1M | 2.4M | 7.9M | 7.5M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: AHCO as "Buy", EHAB as "Hold", OPCH as "Buy", UNH as "Buy", CVS as "Buy". Consensus price targets imply 57.9% upside for OPCH (target: $32) vs -1.9% for EHAB (target: $14). For income investors, CVS offers the higher dividend yield at 2.95% vs UNH's 2.29%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $14.00 | $13.53 | $32.38 | $385.43 | $96.75 |
| # AnalystsCovering analysts | 12 | 11 | 14 | 52 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +2.3% | +3.0% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 1 | 25 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $8.70 | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +9.7% | +1.6% | 0.0% |
AHCO leads in 1 of 6 categories (Valuation Metrics). OPCH leads in 1 (Profitability & Efficiency). 3 tied.
AHCO vs EHAB vs OPCH vs UNH vs CVS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AHCO or EHAB or OPCH or UNH or CVS a better buy right now?
For growth investors, Option Care Health, Inc.
(OPCH) is the stronger pick with 13. 0% revenue growth year-over-year, versus -0. 5% for AdaptHealth Corp. (AHCO). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 1x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate AdaptHealth Corp. (AHCO) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AHCO or EHAB or OPCH or UNH or CVS?
On trailing P/E, Option Care Health, Inc.
(OPCH) is the cheapest at 16. 1x versus CVS Health Corporation at 65. 1x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 2x.
03Which is the better long-term investment — AHCO or EHAB or OPCH or UNH or CVS?
Over the past 5 years, Option Care Health, Inc.
(OPCH) delivered a total return of +23. 1%, compared to -54. 7% for AdaptHealth Corp. (AHCO). Over 10 years, the gap is even starker: UNH returned +228. 3% versus EHAB's -44. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AHCO or EHAB or OPCH or UNH or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
13β versus AdaptHealth Corp. 's 0. 72β — meaning AHCO is approximately 459% more volatile than CVS relative to the S&P 500. On balance sheet safety, UnitedHealth Group Incorporated (UNH) carries a lower debt/equity ratio of 77% versus 125% for AdaptHealth Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — AHCO or EHAB or OPCH or UNH or CVS?
By revenue growth (latest reported year), Option Care Health, Inc.
(OPCH) is pulling ahead at 13. 0% versus -0. 5% for AdaptHealth Corp. (AHCO). On earnings-per-share growth, the picture is similar: Enhabit, Inc. grew EPS 97. 1% year-over-year, compared to -185. 2% for AdaptHealth Corp.. Over a 3-year CAGR, OPCH leads at 12. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AHCO or EHAB or OPCH or UNH or CVS?
Option Care Health, Inc.
(OPCH) is the more profitable company, earning 3. 7% net margin versus -2. 2% for AdaptHealth Corp. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EHAB leads at 6. 0% versus 2. 6% for CVS. At the gross margin level — before operating expenses — EHAB leads at 46. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AHCO or EHAB or OPCH or UNH or CVS more undervalued right now?
On forward earnings alone, Option Care Health, Inc.
(OPCH) trades at 11. 2x forward P/E versus 22. 9x for Enhabit, Inc. — 11. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPCH: 57. 9% to $32. 38.
08Which pays a better dividend — AHCO or EHAB or OPCH or UNH or CVS?
In this comparison, CVS (3.
0% yield), UNH (2. 3% yield) pay a dividend. AHCO, EHAB, OPCH do not pay a meaningful dividend and should not be held primarily for income.
09Is AHCO or EHAB or OPCH or UNH or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
13), 3. 0% yield). Both have compounded well over 10 years (CVS: +6. 6%, AHCO: +16. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AHCO and EHAB and OPCH and UNH and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AHCO is a small-cap quality compounder stock; EHAB is a small-cap quality compounder stock; OPCH is a small-cap deep-value stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap quality compounder stock. UNH, CVS pay a dividend while AHCO, EHAB, OPCH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.